Day: June 8, 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.telesisbio.com/news-events/events. The replay of the webcast will be available for 90 days.

About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly^® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp^® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding the anticipated use of proceeds from the financing, as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (SEC) on March 22, 2023, as amended on May 17, 2023 and in our Quarterly Report on Form 10-Q, which was filed with the SEC on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com

GlobeNewswire Distribution ID 8854405

Funding will accelerate Cohere’s leadership position giving enterprises the power of AI on the cloud platform of their choice, keeping their data private and secure

SAN FRANCISCO and TORONTO, June 08, 2023 (GLOBE NEWSWIRE) — Cohere, the leading AI platform for enterprise, today announced $270M in new capital as part of its Series C financing. Inovia Capital led the round, with additional participation from a diverse group of global institutional and strategic investors, including NVIDIA, Oracle, Salesforce Ventures, DTCP, Mirae Asset, Schroders Capital, SentinelOne, Thomvest Ventures, and returning investor Index Ventures. This group represents investors from the USA, Canada, Korea, the UK, and Germany, and includes some of the most respected technology companies in the world.

“AI will be the heart that powers the next decade of business success,” said Aidan Gomez, CEO and co-founder, Cohere. “As the early excitement about generative AI shifts toward ways to accelerate businesses, companies are looking to Cohere to position them for success in a new era of technology. The next phase of AI products and services will revolutionize business, and we are ready to lead the way.”

“We are at the beginning of a new era driven by accelerated computing and generative AI,” said Jensen Huang, founder and CEO of NVIDIA. “The team at Cohere has made foundational contributions to generative AI. Their service will help enterprises around the world harness these capabilities to automate and accelerate.”

AI Built for Enterprise
Cohere’s AI platform is uniquely designed for enterprises, offering data-secure deployment options in companies’ existing cloud environments, customization, and customer support. This includes an ecosystem of consulting and system integrator partners to help enterprises at any stage in their AI journey.

Cohere’s enterprise AI suite is cloud-agnostic, offering the highest levels of flexibility and data privacy. The platform is built to be available on every cloud provider, deployed inside a customers’ existing cloud environment, virtual private cloud (VPC), or even on-site, to meet companies where their data is. This empowers businesses to transform existing products and build the next era-defining generation of innovative solutions all while keeping their data secure.

“Our entire raison d’être is to invest in great entrepreneurs who have great worldwide mission and ambitions,” said Steve Woods, CTO and Partner, Inovia Capital. “Very few ideas can fundamentally change society and add more value to humankind. This is obviously one such opportunity and we are thrilled to partner with Cohere to be a part of it.”

Today’s news comes on the heels of Cohere’s momentum in several areas: a recent announcement to collaborate with Salesforce Ventures to advance generative AI to realize business value; an engagement with LivePerson to supercharge customer experiences; and a host of additional demand and interest from the enterprise market. As Cohere continues to advance its industry-leading technology, Stanford’s most recent language model evaluation has also ranked Cohere’s Command model highly in accuracy over comparable models. Meanwhile, Cohere recently released the first-ever publicly available multilingual understanding model trained on authentic data from native speakers; it’s equipped to read and understand over 100 of the world’s most commonly spoken languages.

“Cohere has a rare combination of top-tier talent, the most innovative technology and is best positioned to seize the global enterprise market opportunity for Generative AI and LLMs,” said Lance Matthews, Managing Director, DTCP. “Our unique fund structure and relationships allows us to gather a coalition of global institutional and strategic investors including Deutsche Telekom to accelerate Cohere’s vision to bring this technology to enterprises worldwide.”

To learn more about Cohere and its growing team, visit cohere.com.

About Cohere
Cohere is the leading AI platform for enterprise. Its world-class AI is uniquely suited to the needs of business, unlocking unprecedented ease-of-use, accessibility, and data privacy. Cohere’s platform is cloud-agnostic, accessible through API as a managed service, and can be deployed on virtual private cloud (VPC) or even on-site to meet companies where their data is, offering the highest levels of flexibility and control. Founded by Google Brain alumni and a co-author of the seminal Transformer research paper, Cohere is on a mission to transform enterprises and their products with AI that unlocks a more intuitive way to generate, search, and summarize information than ever before. The company is backed by group of global institutional and strategic investors including DTCP, Index Ventures, Inovia Capital, Mirae Asset, NVIDIA, Oracle, Radical Ventures, Salesforce Ventures, Section 32, and Tiger Global, as well as several AI luminaries, including Geoffrey Hinton, Jeff Dean, Fei-Fei Li, Pieter Abbeel, and Raquel Urtasun.

Media Contact
press@cohere.com

GlobeNewswire Distribution ID 8854627

• The studies also showed 18-40% lower costs incurred from ER visits and hospitalizations after 1 year for PAP-adherent OSA patients with diastolic and systolic heart failure, respectively
• A third study estimates over 200 million women have mild obstructive sleep apnea worldwide

INDIANAPOLIS, June 08, 2023 (GLOBE NEWSWIRE) — People with heart failure and obstructive sleep apnea (OSA) can significantly reduce hospitalizations and ER visits as well as related costs by being adherent on positive airway pressure (PAP) therapy, according to two studies supported by ResMed (NYSE: RMD, ASX: RMD) and presented at SLEEP 2023.

Key Results
One retrospective study showed people with OSA and systolic heart failure and adherent to PAP had 24% fewer ER visits and incurred 40% lower costs related to hospitalizations and ER visits over 1 year ($3,500 vs. $5,879) compared to non-adherent patients. The study analyzed 1,472 people, exactly half adherent on PAP, half non-adherent.

The second retrospective study showed people with OSA and diastolic heart failure and adherent to PAP had 36% fewer ER visits, 57% fewer hospitalizations, and incurred 18% lower related costs (an average $12,732 vs. $15,610) over 1 year. This study analyzed 1,926 people, again exactly half adherent on PAP, half non-adherent. It also found that converting a non-adherent PAP user in this study to an adherent one would save them an average 1.25 visits.

The studies hold significant implications for managing heart failure patients, since 76% of them also have sleep apnea.¹

“Since 3 out of 4 people with heart failure also have sleep apnea,¹ these findings underscore the significant role PAP treatment plays in keeping people healthy and out of the hospital,” said Fatima Sert Kuniyoshi, MSc, PhD, lead author and ResMed clinical research director. “I hope this leads to a greater emphasis on PAP prescription and monitoring for the sake of patients as well as the hospitals and ERs that would otherwise require added beds and resources to care for them.”

Also from SLEEP: 200 million women have mild OSA
ResMed supported 10 abstracts presented this week at SLEEP 2023, including a global multi-study analysis that estimated over 200 million women worldwide have mild obstructive sleep apnea. That’s equal to 13.4% of women ages 30-70 – or over 1 in 8.

The study’s abstract points out that while PAP treatment is beneficial in treating mild OSA, the key to optimizing health outcomes is first diagnosing it – particularly in women: “Females with OSA tend to be milder than their male counterparts, with lower AHIs, less oxygen desaturations, and different symptoms such as fatigue and insomnia. [Therefore], females with mild OSA are at risk of being underdiagnosed and undertreated.”

Overall, an estimated 936 million people worldwide have sleep apnea, ranging from mild (5-14 apneic events per hour) to severe (over 30 per hour).²

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

1 Oldenburg O et al. Eur J Heart Fail 2007
2 Benjafield AV et al. Lancet Respir Med 2019

For Media	For Investors
Kristin Deuber	Amy Wakeham
resmed@allisonpr.com	investorrelations@resmed.com
Rowena Kelley
news@resmed.com

GlobeNewswire Distribution ID 8854625

Boston, June 08, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of Property and Casualty (P&C) and general insurance, earns Luminary status in Celent’s 2023 North America and global reports, Insurer Stand-Alone Rating Engines. Duck Creek’s rating solutions have been recognized in the report’s highest-ranking category for advanced technology and breadth of functionality.

This report provides an overview of Duck Creek Rating, which enables customers to rate 583,000 quotes per hour/per server of complex personal lines policies in a 100% horizontally scalable manner. In North America and across the globe, Duck Creek maintains an open platform and open ecosystem philosophy, offering over 100 pre-built and validated integration accelerators. This includes Duck Creek Rating Anywhere Integrations with Coherent, Akur8, AAIS, and Verisk. Celent’s report profiles key stand-alone rating engines and provides an overview of their functionality and technology. The report equips P&C insurance carriers with the knowledge and insights to evaluate the market’s best stand-alone rating engines for their business.

“Duck Creek is proud to continue to earn Celent’s highest Luminary ranking in North America and globally for our rating solutions,” said Jess Keeney, Chief Product & Technology Officer, Duck Creek Technologies. “We are continuously seeking ways to modernize our technology and create evergreen solutions that cultivate a better user experience for our customers. Deploying frequent, fully automated updates with configurability enables us to do this.”

“Duck Creek was one of only two named Luminaries in the report, which is our highest designation,” said Karlyn Carnahan, Head of Insurance for Celent. “Not only does the distinction celebrate the most advanced technology in the rating space, but it also recognizes the solutions with the most expansive functionality. Duck Creek’s solution ranked high in both categories.”

About Celent

Celent is a research and advisory firm dedicated to helping financial institutions formulate comprehensive business and technology strategies. Celent publishes reports identifying trends and best practices in financial services technology and conducts consulting engagements for financial institutions looking to use technology to enhance existing business processes or launch new business strategies. With a team of internationally experienced analysts, Celent is uniquely positioned to offer strategic advice and market insights on a global basis. Celent is a member of the Oliver Wyman Group, which is a wholly owned subsidiary of Marsh McLennan Companies. [NYSE: MMC]. For more information, visit www.celent.com. Follow Celent on Twitter @Celent_Research.

About Duck Creek Technologies

Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and Twitter.

Carley Bunch
Duck Creek Technologies
+1 201 962 6091
carley.bunch@duckcreek.com

GlobeNewswire Distribution ID 8854376

WASHINGTON, June 08, 2023 (GLOBE NEWSWIRE) — Today, EB5 Capital announced the closing of its $40 million preferred equity investment in Daniel Corporation’s Hutchinson Island (JF38) apartment project, located in Savannah, Georgia.

EB5 Capital is making a $40 million preferred equity investment in Daniel Corporation’s 288-unit, Class A multifamily property located across the Savannah River from Historic Downtown Savannah. The project is near the Convention Center and The Westin Harbor Golf Resort and will consist of six residential buildings that are four stories in height with 462 parking spaces. Hutchinson Island (JF38) is scheduled to break ground imminently, and the first units are expected to be delivered in early 2025.

“Savannah has seen significant job growth and capital investment in recent years, following the increased economic activity at the Port of Savannah,” said Jonathan Mullen, EB5 Capital’s Senior Vice President of Investments. “Additionally, Savannah has demonstrated strong multifamily market fundamentals, posting positive net absorption in 17 of the past 20 quarters along with significant annual rent growth.”

Due to the escalating interest rates and the challenges confronting U.S. banks, many lenders have chosen to pull back and adopt stricter lending standards, leading to challenges for borrowers to fully capitalize development deals. “The preferred equity investment from EB5 Capital enabled us to significantly reduce the amount of common equity required and create a capital stack accretive to Daniel Corporation and our partners,” said Carter Bryars, Daniel Corporation’s Chief Operating Officer.

EB5 Capital provides preferred equity investments for ground-up development across the United States. The company has successfully raised approximately one billion dollars since inception and continues to seek investments in multifamily assets with sponsors that have a proven track record of success.

This is EB5 Capital’s first partnership with Daniel Corporation, a reputable developer founded in 1964 and based in Birmingham, Alabama.  Daniel has $1.2 billion in active project investments, primarily through development and management platforms, and has developed or managed over 20,000 multifamily units and over 20 million square feet of commercial and industrial space.

About EB5 Capital

EB5 Capital provides qualified foreign investors with opportunities to invest in job-creating commercial real estate projects under the United States Immigrant Investor Program (EB-5 Visa Program). As one of the oldest and most active Regional Center operators in the country, the firm has raised approximately one billion dollars of foreign capital across more than 30 EB-5 projects. Headquartered in Washington, DC, EB5 Capital’s distinguished track record and leadership in the industry has attracted investors from over 70 countries. Please visit www.eb5capital.com for more information.

Contact:
Katherine Willis
Director, Marketing & Communications
media@eb5capital.com 

GlobeNewswire Distribution ID 8854863

Global Liver Institute Convenes Largest Number of Community Events around the World in the 6 Years of International NASH Day

Washington, D.C., June 08, 2023 (GLOBE NEWSWIRE) — Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most common liver disease in the world – nonalcoholic fatty liver disease (NAFLD) – and it’s more severe form, nonalcoholic steatohepatitis (NASH).
Fatty liver disease is a condition in which excess fat builds up in the liver, which can lead to scarring and cirrhosis (permanent damage that impairs liver function). An estimated 25% of the global population, or about 2 billion people, are affected by NAFLD. 20% of those with NAFLD progress to NASH.
International NASH Day 2023 is endorsed by 30 medical specialty societies from around the world, and more than 50 global organizations, from research institutions to community organizations to medical centers and more, will be hosting events to inform and educate their communities.
“By releasing new, multilingual resources to help patients access NASH diagnostics and treatment, leading even more awareness and educational events worldwide, and continuing to foster opportunities for patients to step up and speak out, GLI and its partners are stepping up for those with or at risk of NASH this year,” shared Donna R. Cryer, JD, President and CEO of Global Liver Institute. “We have been heartened through collaboration with the broader patient advocacy community on health technology assessment (HTA) and regulatory processes. Together we have made certain that the patient voice is the clear, powerful force that it ought to be.”
While NASH can develop at any point in life, many of the factors that heighten an individual’s risk of developing NASH are well-known, including overweight or obesity, type 2 diabetes, and high blood pressure.
Despite established risk factors, too often patients in high-risk groups are still not triaged, not screened, and not connected to the care they require. We are grateful that, just this year, several societies have updated their treatment guidelines for identifying and caring for NAFLD/NASH to reflect our best current understanding of the disease. We are grateful to the scientists who have expanded our understanding of – and ability to control – the disease. It is time for health systems to step up and invest effort in operationalizing these new guidelines.

We urge health system leaders to step up and examine the NASH patient pathway, identify where patients are lost, and bolster those processes.
We encourage primary care and endocrinology providers to step up and learn which of their patients are at heightened risk of NAFLD/NASH – and to connect them to the screening they need.
We challenge the media to step up against the stigma and cover stories about NAFLD/NASH and liver health, especially when discussing obesity, type 2 diabetes, and other risk factors.
We implore regulators to step up for the livelihood of the millions of patients around the world whose lives are affected by NAFLD/NASH.

Clear, strong connections between primary care providers, specialists, and intervention support are all critical – and within reach – to help more patients find and stop the progression of NASH while they have the opportunity.
“It can be overwhelming how widespread the chronic, progressive disease of NAFLD and NASH has become. Those at risk should know they are supported and empowered to step up for a healthier liver,” encouraged Jeff McIntyre, VP of Liver Health Programs at Global Liver Institute. “Ask your doctor for a screening if you have a risk factor – and receive the treatment you need before the disease progresses. Individuals can make small changes with big impacts to support better liver health through better nutrition and incorporating more movement into their daily habits. Although fatty liver disease can progress, it can be controlled if caught early. Get screened now for a healthy liver.”
It’s time to #StepUpforNASH!

Join the Movement
Get tested! Check if you are at risk for NAFLD/NASH and make a note to talk to your primary care provider at your next appointment.
Support the #NASHday social media campaign using hashtags #NASHday #StepUpforNASH. Please direct any additional questions to NASHday@globalliver.org.

About Global Liver Institute 
Global Liver Institute (GLI) is a patient-driven 501(c)3 nonprofit organization headquartered in Washington, DC, with offices in the EU and UK, founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver disease and the importance of liver health to well-being. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to improve research, care, and policy. By bringing together more than 200 community-based, national, and international organizations across its councils, campaigns, and events, GLI equips advocates to identify and solve the problems that matter to liver patients. Follow GLI on Twitter, Facebook, Instagram, LinkedIn, and YouTube. GLI is the global host of International NASH Day.
International NASH Day and its logo are registered trademarks of Global Liver Institute.

Christine Maalouf
Global Liver Institute
communications@globalliver.org

GlobeNewswire Distribution ID 8854884

NAPLES, Italy, June 08, 2023 (GLOBE NEWSWIRE) — Intesa Sanpaolo presented today in Naples new measures dedicated to the development of the tourism industry, vital for the Italian and in particular the southern Italian economy, to support the growth of businesses in the sector and seize the opportunities provided by the NRRP and ministerial initiatives. The bank is making €10 billion of new credit available, of which €3 billion is earmarked for businesses in southern Italy, in addition to the more than €7 billion already allocated to companies in the sector since the pandemic to date. The initiative aims to encourage new investments and strengthen the ecological transition of hospitality businesses along three key axes: upgrading and raising the quality standards of facilities, environmental sustainability of supply through the renovation of facilities and services, and digitisation of the service model.

“The investment is aimed in particular at upgrading the facilities in terms of quality, but we also aim to increase their size in terms of beds,” said Stefano Barrese, head of the Banca dei Territori Division of Intesa Sanpaolo. “We know”, Barrese continued, “that integrated tourism is the element that creates the greatest impact from a growth perspective. In addition, we want to facilitate investment in digital and environmental redevelopment. We need healthy competition with northern Italy. There are certainly great opportunities in a sector where we have a lot to teach,” he concluded.

Anna Roscio, head of the Corporate Sales & Marketing Department at Intesa Sanpaolo, said: “Today we are launching a new initiative for tourism at a national level, with a particular focus on the South, which aims to support businesses in the sector in their efforts to achieve ecological transition and sustainability”. “We intend to make available to entrepreneurs,” she pointed out, “lines of financing on favourable terms that can be used for hotel upgrading. We believe that the consumer trend is pointing towards a greater focus on quality in hospitality, opting for hotels that have already addressed the issue of sustainability, and financing can be the driving force behind this transformation.”

On the subject of SEZs, Giuseppe Nargi, Regional Director of Campania, Calabria and Sicily at Intesa Sanpaolo, commented: “Since 2017 we have been supporting the SEZs, which are finally an operational reality. In Campania, the commissioners are operating very well, and we can now start to see several dozen interventions that translate into new investments, new jobs, redevelopment of industrial areas and, above all, development.”

For more information:
Press Office LaPresse – ufficio.stampa@lapresse.it

A video accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/1c58be7f-2ab2-4880-9771-626db06f855b

GlobeNewswire Distribution ID 8854847